218 related articles for article (PubMed ID: 25259743)
1. Paricalcitol and endothelial function in chronic kidney disease trial.
Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F
Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743
[TBL] [Abstract][Full Text] [Related]
2. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients.
Zoccali C; Torino C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Ghiadoni L; Thadhani R; Tripepi G; Mallamaci F
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):581-589. PubMed ID: 27113290
[TBL] [Abstract][Full Text] [Related]
3. Paricalcitol, Microvascular and Endothelial Function in Non-Diabetic Chronic Kidney Disease: A Randomized Trial.
Lundwall K; Jörneskog G; Jacobson SH; Spaak J
Am J Nephrol; 2015; 42(4):265-73. PubMed ID: 26496210
[TBL] [Abstract][Full Text] [Related]
4. Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease.
Thethi TK; Bajwa MA; Ghanim H; Jo C; Weir M; Goldfine AB; Umpierrez G; Desouza C; Dandona P; Fang-Hollingsworth Y; Raghavan V; Fonseca VA
J Diabetes Complications; 2015 Apr; 29(3):433-7. PubMed ID: 25633573
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor activation by paricalcitol and insulin resistance in CKD.
Spoto B; Pizzini P; Cutrupi S; Tripepi G; Curatola G; Mallamaci F; Zoccali C
Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):291-297. PubMed ID: 29307660
[TBL] [Abstract][Full Text] [Related]
6. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial.
D'arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
Nephrol Dial Transplant; 2019 May; 34(5):819-824. PubMed ID: 29668990
[TBL] [Abstract][Full Text] [Related]
8. [Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease].
Milovanova LIu; Dobrosmyslov IA; Milovanov IuS
Ter Arkh; 2014; 86(6):52-6. PubMed ID: 25095656
[TBL] [Abstract][Full Text] [Related]
9. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
Coyne DW; Andress DL; Amdahl MJ; Ritz E; de Zeeuw D
Nephrol Dial Transplant; 2013 Sep; 28(9):2260-8. PubMed ID: 23787544
[TBL] [Abstract][Full Text] [Related]
10. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.
Thadhani R; Appelbaum E; Pritchett Y; Chang Y; Wenger J; Tamez H; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Packham D; Singh B; Zehnder D; Shah A; Pachika A; Manning WJ; Solomon SD
JAMA; 2012 Feb; 307(7):674-84. PubMed ID: 22337679
[TBL] [Abstract][Full Text] [Related]
12. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
[TBL] [Abstract][Full Text] [Related]
13. Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial.
Spoto B; Pizzini P; Tripepi G; Mallamaci F; Zoccali C
Nephrol Dial Transplant; 2018 Oct; 33(10):1764-1769. PubMed ID: 29304245
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric effect of oral paricalcitol in chronic kidney disease.
Agarwal R; Acharya M; Tian J; Hippensteel RL; Melnick JZ; Qiu P; Williams L; Batlle D
Kidney Int; 2005 Dec; 68(6):2823-8. PubMed ID: 16316359
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D and methylarginines in chronic kidney disease (CKD).
Torino C; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
PLoS One; 2017; 12(10):e0185449. PubMed ID: 28976989
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral paricalcitol therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism.
Giakoumis M; Tsioufis C; Dimitriadis K; Sonikian M; Kasiakogias A; Andrikou E; Kalos T; Konstantinidis D; Filis K; Petras D; Tousoulis D
Hellenic J Cardiol; 2019; 60(2):108-113. PubMed ID: 29305902
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
Webb NJA; Lerner G; Warady BA; Dell KM; Greenbaum LA; Ariceta G; Hoppe B; Linde P; Lee HJ; Eldred A; Dufek MB
Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
[TBL] [Abstract][Full Text] [Related]
18. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
19. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
Wang AY; Fang F; Chan J; Wen YY; Qing S; Chan IH; Lo G; Lai KN; Lo WK; Lam CW; Yu CM
J Am Soc Nephrol; 2014 Jan; 25(1):175-86. PubMed ID: 24052631
[TBL] [Abstract][Full Text] [Related]
20. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
